Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders), By Product, By Region, And Segment Forecasts, 2022 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation & Scope
                       1.1.1. Production Technology
                       1.1.2. Application
                       1.1.3. End-user
                       1.1.4. Regional scope
                       1.1.5. Estimates and forecast timeline
                   1.2. Research Methodology
                   1.3. Information Procurement
                       1.3.1. Purchased database
                       1.3.2. GVR’s internal database
                       1.3.3. Secondary sources
                       1.3.4. Primary research
                       1.3.5. Details of primary research
                   1.4. Information or Data Analysis
                       1.4.1. Data analysis models
                   1.5. Market Formulation & Validation
                   1.6. Model Details
                       1.6.1. Commodity flow analysis (Model 1)
                           1.6.1.1. Approach 1: Commodity flow approach
                       1.6.2. Volume price analysis (Model 2)
                           1.6.2.1. Approach 2: Volume price analysis
                   1.7. List of Secondary Sources
                   1.8. List of Primary Sources
                   1.9. Objectives
                       1.9.1. Objective 1
                       1.9.2. Objective 2
Chapter 2. Executive Summary
                   2.1. Market Outlook
Chapter 3. Biosimilar Contract Manufacturing Market Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent market outlook
                       3.1.2. Related/ancillary market outlook
                   3.2. Penetration & Growth Prospect Mapping
                   3.3. Market Dynamics
                       3.3.1. Market driver analysis
                           3.3.1.1. Increasing disease prevalence
                           3.3.1.2. Low cost of Biosimilar
                           3.3.1.3. Growing R&D investments in Biosimilars
                       3.3.2. Market restraint analysis
                           3.3.2.1. Quality Issues associated with Contract Manufacturing
                           3.3.2.2. Limited outsourcing amongst well-established biopharmaceutical manufacturers
                   3.4. Biosimilar Contract Manufacturing Market Analysis Tools
                       3.4.1. Industry Analysis - Porter’s Five Forces
                       3.4.2. PESTEL Analysis
                       3.4.3. Major Deals & Strategic Alliances Analysis
                   3.5. Covid-19 Impact Analysis
Chapter 4. Biosimilar Contract Manufacturing Market: Product Estimates & Trend Analysis
                   4.1. Definitions and Scope
                   4.2. Biosimilar Contract Manufacturing Market Share, 2021 & 2030
                       4.2.1. Recombinant Non-Glycosylated Proteins
                           4.2.1.1. Recombinant Non-Glycosylated Proteins market estimates and forecast, 2018 to 2030 (USD Billion)
                       4.2.2. Recombinant Glycosylated Proteins
                           4.2.2.1. Recombinant Glycosylated Proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 5. Biosimilar Contract Manufacturing Market: Production Technology Estimates & Trend Analysis
                   5.1. Definitions and Scope
                   5.2. Biosimilar Contract Manufacturing Market Share, 2021 & 2030
                       5.2.1. Mammalian
                           5.2.1.1. Mammalian market estimates and forecast, 2018 to 2030 (USD Billion)
                       5.2.2. Non-Mammalian
                           5.2.2.1. Non-Mammalian market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 6. Biosimilar Contract Manufacturing Market: Application Estimates & Trend Analysis
                   6.1. Definitions and Scope
                   6.2. Biosimilar Contract Manufacturing Market Share, 2021 & 2030
                       6.2.1. Oncology
                           6.2.1.1. Oncology market estimates and forecast, 2018 to 2030 (USD Billion)
                       6.2.2. Blood Disorders
                           6.2.2.1. Blood Disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
                       6.2.3. Growth Hormonal Deficiency
                           6.2.3.1. Growth Hormonal Deficiency market estimates and forecasts, 2018 to 2030 (USD Billion)
                       6.2.4. Rheumatoid Arthritis
                           6.2.4.1. Rheumatoid Arthritis market estimates and forecasts, 2018 to 2030 (USD Billion)
                       6.2.5. Chronic & Autoimmune Diseases
                           6.2.5.1. Chronic & Autoimmune Diseases market estimates and forecasts, 2018 to 2030 (USD Billion)
                       6.2.6. Others
                           6.2.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 7. Biosimilar Contract Manufacturing Market: Regional Estimates & Trend Analysis
                   7.1. Regional market share analysis, 2021 & 2030
                   7.2. North America
                       7.2.1. U.S.
                           7.2.1.1. U.S. market estimates and forecasts, 2018 - 2030
                       7.2.2. Canada
                           7.2.2.1. Canada market estimates and forecasts, 2018 - 2030
                   7.3. Europe
                       7.3.1. U.K.
                           7.3.1.1. U.K. market estimates and forecasts, 2018 - 2030
                       7.3.2. Germany
                           7.3.2.1. Germany market estimates and forecasts, 2018 - 2030
                       7.3.3. France
                           7.3.3.1. France market estimates and forecasts, 2018 - 2030
                       7.3.4. Italy
                           7.3.4.1. Italy market estimates and forecasts, 2018 - 2030
                       7.3.5. Spain
                           7.3.5.1. Spain market estimates and forecasts, 2018 - 2030
                   7.4. Asia Pacific
                       7.4.1. Japan
                           7.4.1.1. Japan market estimates and forecasts, 2018 - 2030
                       7.4.2. China
                           7.4.2.1. China market estimates and forecasts, 2018 - 2030
                       7.4.3. India
                           7.4.3.1. India market estimates and forecasts, 2018 - 2030
                       7.4.4. Australia
                           7.4.4.1. Australia market estimates and forecasts, 2018 - 2030
                       7.4.5. South Korea
                           7.4.5.1. South Korea market estimates and forecasts, 2018 - 2030
                   7.5. Latin America
                       7.5.1. Brazil
                           7.5.1.1. Brazil market estimates and forecasts, 2018 - 2030
                       7.5.2. Mexico
                           7.5.2.1. Mexico market estimates and forecasts, 2018 - 2030
                       7.5.3. Argentina
                           7.5.3.1. Argentina market estimates and forecasts, 2018 - 2030
                   7.6. MEA
                       7.6.1. South Africa
                           7.6.1.1. South Africa market estimates and forecasts, 2018 - 2030
                       7.6.2. Saudi Arabia
                           7.6.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030
Chapter 8. Competitive Landscape
                   8.1. Company Profiles
                       8.1.1. Boehringer Ingelheim Biopharmaceuticals GmbH
                           8.1.1.1. Company overview
                           8.1.1.2. Product benchmarking
                           8.1.1.3. Strategic initiatives
                       8.1.2. Lonza
                           8.1.2.1. Company overview
                           8.1.2.2. Financial performance
                           8.1.2.3. Product benchmarking
                           8.1.2.4. Strategic initiatives
                       8.1.3. Catalent Inc
                           8.1.3.1. Company overview
                           8.1.3.2. Financial performance
                           8.1.3.3. Product benchmarking
                           8.1.3.4. Strategic initiatives
                       8.1.4. Biocon
                           8.1.4.1. Company overview
                           8.1.4.2. Financial performance
                           8.1.4.3. Product benchmarking
                           8.1.4.4. Strategic initiatives
                       8.1.5. IQVIA Inc.
                           8.1.5.1. Company overview
                           8.1.5.2. Financial performance
                           8.1.5.3. Product benchmarking
                           8.1.5.4. Strategic initiatives
                       8.1.6. AGC Biologics.
                           8.1.6.1. Company overview
                           8.1.6.2. Financial performance
                           8.1.6.3. Product benchmarking
                           8.1.6.4. Strategic initiatives
                       8.1.7. Samsung Biologics.
                           8.1.7.1. Company overview
                           8.1.7.2. Financial performance
                           8.1.7.3. Product benchmarking
                           8.1.7.4. Strategic initiatives
                       8.1.8. WuXi Biologics.
                           8.1.8.1. Company overview
                           8.1.8.2. Financial performance
                           8.1.8.3. Product benchmarking
                           8.1.8.4. Strategic initiatives
                       8.1.9. Element Materials Technology
                           8.1.9.1. Company overview
                           8.1.9.2. Financial performance
                           8.1.9.3. Product benchmarking
                           8.1.9.4. Strategic initiatives
                       8.1.10. Rentschler Biopharma SE
                           8.1.10.1. Company overview
                           8.1.10.2. Financial performance
                           8.1.10.3. Product benchmarking
                           8.1.10.4. Strategic initiatives
                       8.1.11. Avid Bioservices, Inc.
                           8.1.11.1. Company overview
                           8.1.11.2. Financial performance
                           8.1.11.3. Product benchmarking
                           8.1.11.4. Strategic initiatives
                       8.1.12. Alcami Corporation, Inc.
                           8.1.12.1. Company overview
                           8.1.12.2. Financial performance
                           8.1.12.3. Product benchmarking
                           8.1.12.4. Strategic initiatives
                       8.1.13. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
                           8.1.13.1. Company overview
                           8.1.13.2. Financial performance
                           8.1.13.3. Product benchmarking
                           8.1.13.4. Strategic initiatives
                       8.1.14. Thermo Fisher Scientific Inc
                           8.1.14.1. Company overview
                           8.1.14.2. Financial performance
                           8.1.14.3. Product benchmarking
                           8.1.14.4. Strategic initiatives
                       8.1.15. Almac Group
                           8.1.15.1. Company overview
                           8.1.15.2. Financial performance
                           8.1.15.3. Product benchmarking
                           8.1.15.4. Strategic initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Biosimilar contract manufacturing market snapshot (2021)
Fig. 11 Biosimilar contract manufacturing market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Biosimilar contract manufacturing market product outlook: Segment dashboard
Fig. 18 Biosimilar contract manufacturing market: product movement analysis
Fig. 19 Recombinant Non-Glycosylated Proteins market, 2018 - 2030 (USD Billion)
Fig. 20 Recombinant Glycosylated Proteins market, 2018 - 2030 (USD Billion)
Fig. 21 Biosimilar contract manufacturing market production technology outlook: Segment dashboard
Fig. 22 Biosimilar contract manufacturing market: production technology movement analysis
Fig. 23 Mammalian market, 2018 - 2030 (USD Billion)
Fig. 24 Non-Mammalian market, 2018 - 2030 (USD Billion)
Fig. 25 Biosimilar contract manufacturing market application outlook: Segment dashboard
Fig. 26 Biosimilar contract manufacturing market: application movement analysis
Fig. 27 Oncology market, 2018 - 2030 (USD Billion)
Fig. 28 Blood Disorders market, 2018 - 2030 (USD Billion)
Fig. 29 Growth Hormone Deficiency market, 2018 - 2030 (USD Billion)
Fig. 30 Rheumatoid Arthritis market, 2018 - 2030 (USD Billion)
Fig. 31 Chronic and Autoimmune Diseases market, 2018 - 2030 (USD Billion)
Fig. 32 Others market, 2018 - 2030 (USD Billion)
Fig. 33 Regional market: Key takeaways
Fig. 34 Regional outlook, 2021 & 2030
Fig. 35 North America market, 2018 - 2030 (USD Billion)
Fig. 36 U.S. market, 2018 - 2030 (USD Billion)
Fig. 37 Canada market, 2018 - 2030 (USD Billion)
Fig. 38 Europe market, 2018 - 2030 (USD Billion)
Fig. 39 U.K. market, 2018 - 2030 (USD Billion)
Fig. 40 Germany market, 2018 - 2030 (USD Billion)
Fig. 41 France market, 2018 - 2030 (USD Billion)
Fig. 42 Italy market, 2018 - 2030 (USD Billion)
Fig. 43 Spain market, 2018 - 2030 (USD Billion)
Fig. 44 Asia Pacific market, 2018 - 2030 (USD Billion)
Fig. 45 China market, 2018 - 2030 (USD Billion)
Fig. 46 India market, 2018 - 2030 (USD Billion)
Fig. 47 Japan market, 2018 - 2030 (USD Billion)
Fig. 48 Australia market, 2018 - 2030 (USD Billion)
Fig. 49 South Korea market, 2018 - 2030 (USD Billion)
Fig. 50 Latin America market, 2018 - 2030 (USD Billion)
Fig. 51 Brazil market, 2018 - 2030 (USD Billion)
Fig. 52 Mexico market, 2018 - 2030 (USD Billion)
Fig. 53 Argentina market, 2018 - 2030 (USD Billion)
Fig. 54 MEA market, 2018 - 2030 (USD Billion)
Fig. 55 South Africa market, 2018 - 2030 (USD Billion)
Fig. 56 Saudi Arabia market, 2018 - 2030 (USD Billion)